{"organizations": [], "uuid": "47dc44074321418269b08a17a20d901c365c5b1e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180416.html", "section_title": "Archive News &amp; Video for Monday, 16 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-idera-pharmaceuticals-enters-into/brief-idera-pharmaceuticals-enters-into-a-clinical-development-support-agreement-with-pillar-partners-foundation-idUSFWN1RT0A2", "country": "US", "domain_rank": 408, "title": "BRIEF-Idera Pharmaceuticals Enters Into A Clinical Development Support Agreement With Pillar Partners Foundation", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.958, "site_type": "news", "published": "2018-04-16T19:16:00.000+03:00", "replies_count": 0, "uuid": "47dc44074321418269b08a17a20d901c365c5b1e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-idera-pharmaceuticals-enters-into/brief-idera-pharmaceuticals-enters-into-a-clinical-development-support-agreement-with-pillar-partners-foundation-idUSFWN1RT0A2", "ord_in_thread": 0, "title": "BRIEF-Idera Pharmaceuticals Enters Into A Clinical Development Support Agreement With Pillar Partners Foundation", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "idera pharmaceuticals inc", "sentiment": "negative"}, {"name": "pillar partners foundation", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16 (Reuters) - Idera Pharmaceuticals Inc:\n* IDERA PHARMACEUTICALS ENTERS INTO A CLINICAL DEVELOPMENT SUPPORT AGREEMENT WITH PILLAR PARTNERS FOUNDATION TO EXPAND THE CLINICAL RESEARCH ON IMO-2125 BEYOND PD-1 REFRACTORY MELANOMA\n* IDERA PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, PILLAR PARTNERS TO PROVIDE DIRECT FUNDING TO EXPAND CLINICAL RESEARCH OF IMO-2125 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-16T19:16:00.000+03:00", "crawled": "2018-04-17T12:27:56.015+03:00", "highlightTitle": ""}